Angiotensin 1-7
Also known as: Ang-(1-7), A(1-7)
Protective peptide of the renin-angiotensin system with vasodilatory and anti-inflammatory effects.
Evidence
Emerging
FDA status
Not FDA-approved
Source
Endogenous heptapeptide, can be synthesized
Overview
Protective peptide of the renin-angiotensin system with vasodilatory and anti-inflammatory effects.
Mechanism of Action
Binds Mas receptor (counterbalances ACE/Ang II pathway), vasodilation via NO/prostaglandin release, anti-fibrotic and anti-proliferative effects, reduces oxidative stress, anti-inflammatory via reduced cytokines, cardioprotective and neuroprotective actions.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Heart and blood vessel effects (animal studies)
- Vasodilation and blood pressure reduction
- Anti-fibrotic effects
- Neuroprotection
- Anti-inflammatory
- Metabolic benefits (improved insulin sensitivity)
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Angiotensin 1-7 isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Preclinical studies, early clinical trials
Heart and metabolic effects are reported in animal studies. Human trials are early and small.
Safety Information
Potential Side Effects
- •Unknown in humans (limited data)
- •Theoretical hypotension
Contraindications
- Under investigation
Interactions
- ⚠May interact with ACE inhibitors and ARBs